Wave Life Sciences Ltd.
NASDAQ:WVEBiotechnology
+$0.10 today
- Market cap
- $560.13M
- Beta
- -1.33
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$0.92
Volume 2.78M
Average 4.86M
WVE EBITDA Margin
EBITDA as a percentage of revenue.
Wave Life Sciences Ltd.NASDAQ: WVE
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -62.2%
EBITDA Margin was -62.2% in Q1 FY2026, up 425.2 pp from a year earlier. On a trailing-twelve-month basis it was -243.2%, down 144.4 pp year over year. Over 3 fiscal years it widened by 3681.3 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 15 analysts of -260.2% for the fiscal year ending Dec 2026, up from -457.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -62.2%+233.1 pp QoQ
- Last fiscal yearDec 2025
- -457.6%-376.0 pp YoY
- LTMMar 2026
- -243.2%-144.4 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -457.6%
- Year-over-year change
- -376.0pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -457.6% | -376.0pp |
| FY2024 | 2024-12-31 | -81.6% | -38.3pp |
| FY2023 | 2023-12-31 | -43.2% | +4095.7pp |
| FY2022 | 2022-12-31 | -4138.9% | -3864.0pp |
| FY2021 | 2021-12-31 | -274.9% | — |
EBITDA Margin vs competitors
How WVE compares with its peers on the latest reported figures
- WVE's LTM Mar 2026 EBITDA Margin of -243.2% is the 6th highest of the 10 companies compared; the peer median is -148.9%.
- Its year-over-year change of -144.4 pp is the 6th highest of 9, against a peer median of -67.1 pp.
- Over three fiscal years its change of +3681.3 pp compares with a peer median of +34.3 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 24.0% | +30.9 pp | +106.3 pp | |
| LTM Mar 2026 | 5.7% | +10.5 pp | +34.3 pp | |
| LTM Sep 2026 | -49.3% | -33.5 pp | +8.7 pp | |
| LTM Sep 2026 | -133.9% | -153.8 pp | -60.9 pp | |
| LTM Mar 2026 | -148.9% | -100.7 pp | -100.7 pp | |
| LTM Mar 2026 | -243.2% | -144.4 pp | +3681.3 pp | |
| LTM Mar 2026 | -319.0% | -184.3 pp | +1328.5 pp | |
| LTM Mar 2026 | -511.5% | -539.6 pp | +799.5 pp | |
| LTM Mar 2026 | -581.9% | +549.6 pp | +308.9 pp | |
| LTM Mar 2026 | -8478.5% | — | -15524.4 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding WVE) | -148.9% | -67.1 pp | +34.3 pp | |
Competitors are the stored peer set for WVE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 40.96M | 3.65M | 113.31M | 108.3M | 42.73M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 8.85M |
| Gross Profit | 40.96M | 3.65M | 113.31M | 108.3M | 33.88M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 79.3% |
| Research & Development | 121.88M | 115.86M | 130.01M | 159.68M | 182.78M |
| Selling, General & Admin | 46.11M | 50.51M | 51.29M | 59.02M | 75.33M |
| Operating Expenses | 167.98M | 166.37M | 181.3M | 218.71M | 249.26M |
| Depreciation & Amortization | 9.84M | 10.11M | 9.21M | 8.66M | 8.85M |
| EBITDA | (112.61M) | (151.03M) | (48.98M) | (88.35M) | (195.53M) |
| EBITDA Margin | -274.9% | -4138.9% | -43.2% | -81.6% | -457.6% |
| Operating Income | (127.02M) | (162.72M) | (68M) | (110.4M) | (215.38M) |
| Operating Margin | -310.1% | -4459.3% | -60.0% | -101.9% | -504.1% |
| Interest Income | 30K | 0 | 0 | 0 | 10.48M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.57M | 1.58M | 9.81M | 13.4M | 11.01M |
| Income Before Tax | (122.45M) | (161.14M) | (58.19M) | (97.01M) | (204.38M) |
| Pre-Tax Margin | -298.9% | -4416.1% | -51.4% | -89.6% | -478.3% |
| Income Tax Expense | (204K) | 681K | (677K) | 0 | 0 |
| Net Income | (122.25M) | (161.82M) | (57.51M) | (97.01M) | (204.38M) |
| Net Margin | -298.4% | -4434.7% | -50.8% | -89.6% | -478.3% |
| EPS (Basic) | (2.36) | (2.05) | (0.54) | (0.70) | (1.21) |
| EPS (Diluted) | (2.36) | (2.05) | (0.54) | (0.70) | (1.21) |
| Weighted Avg Shares | 51.83M | 78.86M | 106.1M | 138.28M | 168.65M |
| Weighted Avg Shares (Diluted) | 51.83M | 78.86M | 106.1M | 138.28M | 168.65M |
Wave Life Sciences Ltd.
NASDAQ:WVE
Intrinsic Alpha fair value
Locked
Current Price
$2.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.